MMI's core product is the Symani Surgical System, a first‑of‑its‑kind robotic platform that pairs the world’s smallest wristed microinstruments with tremor‑reduction and motion‑scaling to enable micro- and supermicrosurgical soft‑tissue procedures. The system is designed to replicate natural hand movements at micro scale to expand treatment options for free flap reconstruction, lymphatic surgery, trauma replantations, microvascular and peripheral nerve repair. MMI plans to commercialize the Symani System in high‑growth markets, expand clinical indications through ongoing studies, and grow hospital partnerships to increase surgeon access to complex procedures. The company will also invest proceeds to accelerate advanced technology capabilities and scale global operational capacity. Financially, MMI has raised over $200 million to date and projects the market for eligible robotic microsurgical procedures will grow from 3 million to 22 million annually by 2028; the Symani System is CE marked in Europe but is not approved or cleared for commercial use in the United States. Medical Microinstruments (MMI) develops a robotic system for intricate microsurgical procedures. The MMI system comprises a robotics platform and wristed microinstruments that provide wrist-like joint movement for surgeons. The technology is intended for delicate operations such as reconstruction after traumatic injuries and tumor removal in the breast, head, and bones. Founded in 2015 near Pisa, the team set out to enhance surgical performance and improve clinical outcomes in microsurgery. MMI has signed a financing agreement with the European Investment Bank granting access to up to €15 million, which will be deployed over the next few years. That loan is backed by a guarantee from the European Fund for Strategic Investments, the main pillar of the Investment Plan for Europe. The company previously raised a €20 million Series A round led by Andera Partners in 2018. Medical Microinstruments (MMI) develops a teleoperated robotic platform for suturing in open surgery using wristed microinstruments. The solution enables surgeons to scale motion and eliminate tremor and aims to facilitate existing procedures and enable new ones across microsurgery, including post-oncological and trauma reconstructions, ophthalmology, organ transplantation and pediatric surgery. The platform is an investigational device and is not yet commercially available. Founded in 2015 and based in Calci, Pisa, Italy, MMI was started by Giuseppe M. Prisco, Carlo Alberto Marcoaldi, Hannah Teichmann and Massimiliano Simi. MMI plans to use the Series A proceeds to accelerate platform development, complete product and clinical development, obtain the CE mark and launch in European markets. The company completed a €20M Series A in 2018.

Total raised

$152M

Funding rounds

3

Latest round

Series C

Latest activity

Feb 2024